EFdA-TP

• Description :

  EFdA-TP is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT) . EFdA-TP inhibits HIV-1 RT with multiple mechanisms[1].

• UNSPSC :

  12352005

• Target :

  DNA/RNA Synthesis; HIV; Reverse Transcriptase

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Cell Cycle/DNA Damage

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/efda-tp.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=[P](O[P](O[P](O)(O)=O)(O)=O)(O)OC[C@]1(O[C@@](C[C@@H]1O)([H])N2C3=NC(F)=NC(N)=C3N=C2)C#C

• Molecular Formula :

  C12H15FN5O12P3

• Molecular Weight :

  533.19

• References & Citations :

  [1]Eleftherios Michailidis, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289 (35) :24533-48.|[2]Martin Markowitz, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. Curr Opin HIV AIDS. 2018 Jul;13 (4) :294-299.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HIV-1

• CAS Number :

  [950913-56-1]